JENBURKT PHARMACEUTICAL L

Operates in the pharmaceuticals sector, reporting FY26 revenue of ₹168.74 crore, up 11.2% year-on-year, with net profit of ₹34.74 crore. The cost structure is unusual for a pharmaceutical — raw materials account for only 5.3% of revenue while employee costs at 29.6% are the largest single line item, pointing to a sales-and-marketing-led model rather than bulk drug manufacturing. Other operating expenses take another 25.4% of revenue, with depreciation at just 1.8% reflecting a relatively asset-light base. The balance sheet is debt-free with zero borrowings and reserves of ₹17,847 lacs as of H1 FY26. Capital expenditure of ₹13.72 crore in FY26 and capital work in progress of ₹5,221 lacs at H1 FY26 indicate ongoing capacity expansion. An exceptional charge of ₹395.11 lakhs was recorded in FY26 due to revised Indian Labour Codes raising gratuity and leave liabilities.